摘要
ILC3s are tissue-resident lymphocytes enriched in the mammalian intestine that crucially orchestrate immunity, inflammation, and tissue homeostasis. ILC3s are fundamentally altered in the intestine of individuals with inflammatory bowel disease, chronic infections, or cancer. Multiple cellular and molecular circuits promote ILC3 activation, including signals derived from microbiota, pathogens, neurons, and dietary stimuli. There has been a recent appreciation of novel pathways that fine-tune or suppress ILC3s in the gut, such as plasticity, circadian rhythm, and adaptive immunity. Group 3 innate lymphoid cells (ILC3s) have emerged as master regulators of intestinal health and tissue homeostasis in mammals. Through a diverse array of cytokines and cellular interactions, ILC3s crucially orchestrate lymphoid organogenesis, promote tissue protection or regeneration, facilitate antimicrobial responses, and directly regulate adaptive immunity. Further, translational studies have found that ILC3 responses are altered in the intestine of defined patient populations with chronic infectious, inflammatory, or metabolic diseases. Therefore, it is essential to broadly understand the signals that activate, suppress, or fine-tune ILC3s in the gut. Here, we discuss recent exciting advances in this field, integrate them into our current understanding of ILC3 biology, and highlight fundamental gaps in knowledge that require additional investigation. Group 3 innate lymphoid cells (ILC3s) have emerged as master regulators of intestinal health and tissue homeostasis in mammals. Through a diverse array of cytokines and cellular interactions, ILC3s crucially orchestrate lymphoid organogenesis, promote tissue protection or regeneration, facilitate antimicrobial responses, and directly regulate adaptive immunity. Further, translational studies have found that ILC3 responses are altered in the intestine of defined patient populations with chronic infectious, inflammatory, or metabolic diseases. Therefore, it is essential to broadly understand the signals that activate, suppress, or fine-tune ILC3s in the gut. Here, we discuss recent exciting advances in this field, integrate them into our current understanding of ILC3 biology, and highlight fundamental gaps in knowledge that require additional investigation. ILC3s expressing CCR6 but not T-bet or NKp46. physiological processes following a daily cycle. small clusters of lymphoid cells with predominantly lineage-negative cells in the lamina propria of the intestine. a mouse model of intestinal damage and inflammation induced by DSS in drinking water. organ system comprising the mouth, esophagus, stomach, and intestine; absorbs energy and nutrients. a term for a group of intestinal disorders characterized by chronic inflammation. organized lymphoid structures derived from CPs and induced by microbiota colonization. a group of cell-surface receptors predominantly expressed by NK cells. ILC3s expressing NKp46 and T-bet but not CCR6. nonpathogenic for the healthy host; become pathogenic when the host is compromised. a set of molecules from microbes that can be recognized by pattern recognition receptors to trigger immune responses. organized and aggregated lymphoid follicles in the small intestine. mice lacking mature T and B lymphocytes. subset of T cells that mediates immunological tolerance. commensal bacteria that attach to the epithelium of the ileum and induce intestinal Th17 cells in mice. metabolites of microbial fermentation of dietary fiber that have fewer than six carbon atoms. a class of receptors that recognize pathogen-associated molecular patterns from microorganisms.